- Home
- GENK vs RNXT Comparison
GENK vs RNXT Comparison
Compare GENK & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | RNXT |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 37.0M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GENK | RNXT |
|---|---|---|
| Price | $2.13 | $0.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.50 | ★ $8.25 |
| AVG Volume (30 Days) | 18.2K | ★ 307.4K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | ★ 62.50 | 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,380,000.00 | $1,123,000.00 |
| Revenue This Year | $4.79 | $194.66 |
| Revenue Next Year | $7.48 | $279.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 15.12 | ★ 2511.63 |
| 52 Week Low | $1.43 | $0.70 |
| 52 Week High | $4.98 | $1.45 |
Technical Indicators
Market Signals| Indicator | GENK | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 54.96 | 49.56 |
| Support Level | $2.20 | $0.81 |
| Resistance Level | $2.30 | $1.07 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 78.94 | 29.60 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.